JP2010531846A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2010531846A5 JP2010531846A5 JP2010513952A JP2010513952A JP2010531846A5 JP 2010531846 A5 JP2010531846 A5 JP 2010531846A5 JP 2010513952 A JP2010513952 A JP 2010513952A JP 2010513952 A JP2010513952 A JP 2010513952A JP 2010531846 A5 JP2010531846 A5 JP 2010531846A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- binding fragment
- fragment
- antagonist
- receptor
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000012634 fragment Substances 0.000 claims 25
- 239000005557 antagonist Substances 0.000 claims 7
- 102000008228 Toll-like receptor 2 Human genes 0.000 claims 5
- 108010060888 Toll-like receptor 2 Proteins 0.000 claims 5
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 4
- 206010071155 Autoimmune arthritis Diseases 0.000 claims 3
- 229940125721 immunosuppressive agent Drugs 0.000 claims 3
- 239000003018 immunosuppressive agent Substances 0.000 claims 3
- 101000831567 Homo sapiens Toll-like receptor 2 Proteins 0.000 claims 2
- 108010002352 Interleukin-1 Proteins 0.000 claims 2
- 102000000589 Interleukin-1 Human genes 0.000 claims 2
- 102000045718 human TLR2 Human genes 0.000 claims 2
- 241000282836 Camelus dromedarius Species 0.000 claims 1
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 claims 1
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 claims 1
- 208000003456 Juvenile Arthritis Diseases 0.000 claims 1
- 206010059176 Juvenile idiopathic arthritis Diseases 0.000 claims 1
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 claims 1
- 239000012826 P38 inhibitor Substances 0.000 claims 1
- 230000006044 T cell activation Effects 0.000 claims 1
- 210000001744 T-lymphocyte Anatomy 0.000 claims 1
- 230000001154 acute effect Effects 0.000 claims 1
- 125000000539 amino acid group Chemical group 0.000 claims 1
- 208000019069 chronic childhood arthritis Diseases 0.000 claims 1
- 230000001684 chronic effect Effects 0.000 claims 1
- 229940111134 coxibs Drugs 0.000 claims 1
- 239000003255 cyclooxygenase 2 inhibitor Substances 0.000 claims 1
- 238000010494 dissociation reaction Methods 0.000 claims 1
- 230000005593 dissociations Effects 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 230000021995 interleukin-8 production Effects 0.000 claims 1
- 201000002215 juvenile rheumatoid arthritis Diseases 0.000 claims 1
- 229960000681 leflunomide Drugs 0.000 claims 1
- VHOGYURTWQBHIL-UHFFFAOYSA-N leflunomide Chemical compound O1N=CC(C(=O)NC=2C=CC(=CC=2)C(F)(F)F)=C1C VHOGYURTWQBHIL-UHFFFAOYSA-N 0.000 claims 1
- 230000001404 mediated effect Effects 0.000 claims 1
- 229960000485 methotrexate Drugs 0.000 claims 1
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 claims 1
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 230000000770 proinflammatory effect Effects 0.000 claims 1
- ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 claims 1
- 210000003289 regulatory T cell Anatomy 0.000 claims 1
- 229960002930 sirolimus Drugs 0.000 claims 1
- QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 claims 1
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IE2007/0468 | 2007-06-28 | ||
| IE20070468 | 2007-06-28 | ||
| US3837208P | 2008-03-20 | 2008-03-20 | |
| US61/038,372 | 2008-03-20 | ||
| IE20080209 | 2008-03-20 | ||
| IE2008/0209 | 2008-03-20 | ||
| PCT/EP2008/058339 WO2009000929A2 (en) | 2007-06-28 | 2008-06-27 | Composition and method for treatment of autoimmune disease |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2010531846A JP2010531846A (ja) | 2010-09-30 |
| JP2010531846A5 true JP2010531846A5 (enExample) | 2011-08-04 |
| JP5554703B2 JP5554703B2 (ja) | 2014-07-23 |
Family
ID=39758798
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010513952A Active JP5554703B2 (ja) | 2007-06-28 | 2008-06-27 | 自己免疫疾患の治療のための組成物および方法 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US8580255B2 (enExample) |
| EP (1) | EP2170392A2 (enExample) |
| JP (1) | JP5554703B2 (enExample) |
| CN (1) | CN101808662A (enExample) |
| AU (1) | AU2008267151B2 (enExample) |
| CA (1) | CA2691784C (enExample) |
| WO (1) | WO2009000929A2 (enExample) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20100278817A1 (en) | 2007-07-05 | 2010-11-04 | Opsona Therapeutics Ltd. | Compounds and methods for the treatment of renal disease |
| WO2011156451A2 (en) * | 2010-06-08 | 2011-12-15 | The Cleveland Clinic Foundation | Compositions and methods for modulating toll-like receptor 2 activation |
| US9981018B2 (en) | 2010-06-08 | 2018-05-29 | The Cleveland Clinic Foundation | Compositions and methods for modulating toll-like receptor 2 activation |
| CA2805989A1 (en) * | 2010-07-19 | 2012-01-26 | Yeda Research And Development Co. Ltd. | Peptides based on the transmembrane domain of a toll-like receptor (tlr) for treatment of tlr-mediated diseases |
| AU2012223366B2 (en) | 2011-03-03 | 2017-02-23 | Quark Pharmaceuticals, Inc. | Oligonucleotide modulators of the toll-like receptor pathway |
| US9796979B2 (en) | 2011-03-03 | 2017-10-24 | Quark Pharmaceuticals Inc. | Oligonucleotide modulators of the toll-like receptor pathway |
| WO2014144686A1 (en) * | 2013-03-15 | 2014-09-18 | University Of Florida Research Foundation | Compunds for treating neurodegenerative proteinopathies |
| WO2016154586A1 (en) * | 2015-03-26 | 2016-09-29 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | Toll-like receptor 2 ligands and methods of making and using thereof |
| EP3307346A4 (en) * | 2015-06-15 | 2019-01-02 | Vital Therapies, Inc. | Composition and method for inducing anti-inflammatory response |
| CN112153897B (zh) | 2018-01-02 | 2023-02-03 | 拉什大学医学中心 | 用于治疗神经病学和其他病症的组合物和方法 |
| WO2020011869A2 (en) | 2018-07-11 | 2020-01-16 | Roche Innovation Center Copenhagen A/S | Antisense oligonucleotides targeting tlr2 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9927332D0 (en) | 1999-11-18 | 2000-01-12 | Leiv Eiriksson Nyfotek As | Novel antibody and uses thereof |
| US7388080B2 (en) * | 2003-08-20 | 2008-06-17 | University Of Massachusetts | Selective inhibition of toll-like receptor-2 |
| ATE510853T1 (de) | 2003-09-23 | 2011-06-15 | Univ Muenchen Tech | Tlr2-antagonistischer antikörper und dessen verwendung |
| WO2005039504A2 (en) * | 2003-10-24 | 2005-05-06 | Eisai Co., Ltd. | Compounds and methods for treating toll-like receptor 2-related diseases and conditions |
| WO2005079419A2 (en) | 2004-02-17 | 2005-09-01 | The Regents Of The University Of California | Methods of treating immunopathological disorders |
| ES2348792T3 (es) * | 2004-12-10 | 2010-12-14 | Novimmune Sa | TERAPIAS COMBINADAS DIRIGIDAS A MÚLTIPLES RECEPTORES TIPO TOLL Y USO DE LAS MISMAS. |
| TW200641353A (en) * | 2005-02-14 | 2006-12-01 | Wyeth Corp | Interleukin-17F antibodies and other IL-17F signaling antagonists and uses therefor |
| EP2139916A1 (en) * | 2007-04-26 | 2010-01-06 | Opsona Therapeutics Limited | Toll-like receptor binding epitope and compositions for binding thereto |
-
2008
- 2008-06-27 JP JP2010513952A patent/JP5554703B2/ja active Active
- 2008-06-27 EP EP08774497A patent/EP2170392A2/en not_active Withdrawn
- 2008-06-27 AU AU2008267151A patent/AU2008267151B2/en active Active
- 2008-06-27 US US12/666,442 patent/US8580255B2/en active Active
- 2008-06-27 CA CA2691784A patent/CA2691784C/en active Active
- 2008-06-27 WO PCT/EP2008/058339 patent/WO2009000929A2/en not_active Ceased
- 2008-06-27 CN CN200880104716A patent/CN101808662A/zh active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2010531846A5 (enExample) | ||
| Chu et al. | Reduction of total IgE by targeted coengagement of IgE B-cell receptor and FcγRIIb with Fc-engineered antibody | |
| ES2514495T3 (es) | Anticuerpos humanizados modificados anti-interleucina-18 | |
| Shaw et al. | Discovery and characterization of olokizumab: a humanized antibody targeting interleukin-6 and neutralizing gp130-signaling | |
| JP2020039360A5 (enExample) | ||
| TWI687440B (zh) | Ｓｔ２ｌ拮抗劑及使用方法 | |
| HRP20231031T1 (hr) | Protutijela protiv sars-cov-2 | |
| FI3592384T3 (fi) | Vasta-aineita, jotka spesifisesti sitoutuvat ihmisen IL-1R7:ään | |
| US10618957B2 (en) | Antibody molecules which bind CD79 | |
| JP2022031635A5 (enExample) | ||
| HRP20191342T1 (hr) | Anti-phf-tau antitijela i njihove upotrebe | |
| JP2012516158A5 (enExample) | ||
| JP2012501670A5 (enExample) | ||
| HRP20171080T1 (hr) | Protutijela s modificiranim affinitetom za fcrn koja potiču uklanjanje antigena | |
| HK1244014A1 (zh) | Cd3/cd38 t细胞重靶向异源二聚体免疫球蛋白及其生产方法 | |
| JP2017522043A5 (enExample) | ||
| EA201001467A1 (ru) | Моноклональное антитело и способ его использования | |
| CA2992372A1 (en) | Antibody molecules which bind cd22 | |
| JP2015501291A5 (enExample) | ||
| JP2012524071A5 (enExample) | ||
| EP3169705A2 (en) | Molecules with specificity for cd79 and cd22 | |
| CA2991179A1 (en) | Antibody molecules which bind cd45 | |
| JP2014111644A5 (enExample) | ||
| RU2011145428A (ru) | АНТИТЕЛА ПРОТИВ TNF-α И ИХ ПРИМЕНЕНИЯ | |
| HRP20221260T1 (hr) | Humanizirana i kimerna monoklonska protutijela za cd47 |